CVR 42559997Public limited company (A/S)Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)Odense CFounded 23 Jul 2021
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Nordic microbes A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
20
CVR, Aug 2026
-1 (-4.8%) over 12 months
Gross profit
4.9M
DKK, annual report 2025
-20.4% on 2024
Result
-11.3M
DKK, annual report 2025
Equity
66.3M
DKK, annual report 2025
Omixholding ApSCVR 42559903, 33.3% to under 50% of capital and votes
PSV Hafnium Fund I K/SCVR 43111531, 5% to under 10% of capital and votes
and 2 moreOperating company
Dandex estimate: 20 employees registered in 2026Morten Østergaard Andersensince 23 Jul 2021
Owners of 5% or more. CVR registers shares in bands, not exact figures.
CVR 4255990333.3% to under 50% of capital and votesnotified 13 Oct 2023since 23 Jul 2021
CVR 431115315% to under 10% of capital and votessince 12 Jul 2024
CVR 433669045% to under 10% of capital and votessince 13 Oct 2023
5% to under 10% of capital and votessince 19 Dec 2024
CVR 100501545% to under 10% of capital and votesnotified 12 Jul 202411 Apr 2022 to 12 Jul 2024
CVR 292114775% to under 10% of capital and votesnotified 13 Oct 20234 Feb 2022 to 13 Oct 2023
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Aug 2026, monthly: 20 employees, 20 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Sep 2021 | Oct 2021 | Nov 2021 | Dec 2021 | Jan 2022 | Feb 2022 | Mar 2022 | Apr 2022 | May 2022 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 2 | 6 | 7 | 6 | 6 | 7 | 8 | 9 | 9 | 12 | 12 | 14 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 14 | 17 | 17 | 19 | 19 | 19 | 18 | 17 | 20 | 20 | 21 | 21 | 21 | 21 | 21 | 20 | 20 | 21 | 21 | 22 | 22 | 22 | 22 | 22 | 22 | 23 | 21 | 21 | 23 | 23 | 22 | 24 | 19 | 20 | 21 | 20 | 20 | 20 | 20 | 20 |
| FTE | 2 | 5 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 9 | 9 | 11 | 12 | 13 | 12 | 13 | 12 | 13 | 12 | 13 | 12 | 15 | 15 | 16 | 17 | 17 | 16 | 15 | 17 | 18 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 21 | 22 | 22 | 22 | 22 | 22 | 22 | 23 | 21 | 21 | 23 | 23 | 22 | 24 | 19 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest Aug 2026, published 21 Oct 2026.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2025, DKK: Gross profit 4.9M, Operating profit -14.9M, Result for the year -11.3M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 67.6M, Equity 66.3M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Gross profit | 3,424 | 4,542 | 6,148 | 4,895 |
| Operating profit | -2,880 | -5,878 | -9,802 | -14,948 |
| Result for the year | -2,161 | -4,526 | -6,523 | -11,316 |
| Equity | 7,877 | 50,682 | 44,159 | 66,299 |
| Total assets | 13,088 | 52,172 | 46,069 | 67,567 |
| Employees (average) | 7 | 15 | 20 | 22 |
| Credit metrics (Dandex calculations) | ||||
| Gross profit growth (vækst i bruttofortjeneste) | Not reportednote 1 | Not reportednote 2 | 35.4% | -14.1% |
| EBITDA | -2,646 | -5,077 | -7,809 | -11,266 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | |||
| Employee growth (vækst i antal ansatte) | Not reportednote 1 | Not reportednote 2 | 33.3% | 10% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | |||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | |||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | |||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | |||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | |||
| Capex (investeringer i anlægsaktiver) | 7,667note 3 | 6,623note 3 | 16,470note 3 | 16,476note 3 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | |||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | |||
Not every period is a full year: 2022 covers 17 months (23 Jul 2021 to 31 Dec 2022). Changes against it compare periods of different length.
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for Nordic microbes A/S:
Have Pro? Sign in.
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move. Implied value is the whole capital after the step at its cash price, not a valuation.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseCashPaid in 1,069,650, cash price 450.00, implied value 217,901,700 | 450.00 | 1,069,650 | 217,901,700 | 484,226 | |
| IncreaseCashPaid in 10,246,986, cash price 464.40, implied value 223,770,676 | 464.40 | 10,246,986 | 223,770,676 | 481,849 | |
| IncreaseCashPaid in 26,593,402, cash price 464.40, implied value 213,523,690 | 464.40 | 26,593,402 | 213,523,690 | 459,784 | |
| IncreaseCash, debt conversion, bonus issue from reservesPaid in 52,203,629, cash price 2,158.49, implied value 868,833,624 | 2,158.49 | 52,203,629 | 868,833,624 | 402,520 | |
| IncreaseCashPaid in 9,998,575, cash price 655.00, implied value 36,198,575 | 655.00 | 9,998,575 | 36,198,575 | 55,265 | |
| FoundingCashPaid in 40,000 | None | 40,000 | None | 40,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Source: CVR, read 18 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 18 Nov 2026.
24 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Vedtægter ændret: 16.06.2026
Kapitalforhøjelsen er besluttet den 16.06.2026.
kr. 2.377,00, indbetalt kontant, kurs 45.000,00.
Kapitalen udgør herefter kr. 484.226,00.
Bestyrelse:
Fratrådte:
Henrik Busch-Larsen, den 25.02.2026.
Tiltrådte:
Christopher Jeremy Horne, den 25.02.2026.
Vedtægter ændret: 16.12.2025
Vedtægter ændret: 02.12.2025
Bestyrelse:
Fratrådte:
Morten Østergaard Andersen, den 02.12.2025, Anders Kjær, den 02.12.2025.
Tiltrådte:
Niels Dengsø Jensen, den 02.12.2025.
Vedtægter ændret: 17.09.2025
Kapitalforhøjelsen er besluttet den 17.09.2025.
kr. 22.065,00, indbetalt kontant, kurs 46.440,00.
Kapitalen udgør herefter kr. 481.849,00.
Vedtægter ændret: 22.07.2025
Kapitalforhøjelsen er besluttet den 22.07.2025.
kr. 57.264,00, indbetalt kontant, kurs 46.440,00.
Kapitalen udgør herefter kr. 459.784,00.
Vedtægter ændret: 09.07.2025
Vedtægter ændret: 21.05.2025
Bestyrelse:
Fratrådte:
CEO Henrik Busch-Larsen, (formand), den 17.12.2024, Thomas Hessellund, den 17.12.2024.
Tiltrådte:
CEO Henrik Busch-Larsen, den 17.12.2024, Thomas Hessellund, (formand), den 17.12.2024.
Vedtægter ændret: 18.10.2024
Nyt navn: Nordic microbes A/S
Nyt binavn: Bioomix A/S
Slettet binavn: Nordic Microbes A/S
Bestyrelse:
Fratrådte:
Julia Magdalena Østergaard Andersen, den 08.05.2024.
Tiltrådte:
Morten Østergaard Andersen, den 08.05.2024.
Vedtægter ændret: 09.02.2024
Virksomheden er omdannet til et aktieselskab med CVR-NR. 42559997
Vedtægter ændret: 13.10.2023
Nyt navn: Bioomix A/S
Nyt binavn: Nordic Microbes A/S
Kapitalforhøjelsen er besluttet den 13.10.2023.
kr. 20.000,00, indbetalt kontant, kurs 215.848,56. kr. 5.239,00, indbetalt ved konvertering af gæld, kurs 172.435,90. kr. 322.016,00, indbetalt ved overførte reserver / overskud, kurs 100,00.
Kapitalen udgør herefter kr. 402.520,00.
Vedtægter ændret: 11.04.2023
Vedtægter ændret: 14.03.2023
Revision:
Tiltrådte:
CVR-NR. 35257691 BAKER TILLY DENMARK GODKENDT REVISIONSPARTNERSELSKAB, Poul Bundgaards Vej 1, 1. sal, 2500 Valby, den 13.03.2023.
Vedtægter ændret: 14.10.2022
Ny adresse: Kochsgade 25, 5000 Odense C
Ny adresse: Kochsgade 23, 5000 Odense C
Vedtægter ændret: 11.04.2022
Kapitalforhøjelsen er besluttet den 11.04.2022.
kr. 15.265,00, indbetalt kontant, kurs 65.500,00.
Kapitalen udgør herefter kr. 55.265,00.
Bestyrelse:
Tiltrådte:
Julia Magdalena Østergaard Andersen, den 11.04.2022, CEO Henrik Busch-Larsen, (formand), den 11.04.2022, Anders Kjær, den 11.04.2022.
Selskabet tegnes af et medlem af bestyrelsen sammen med en direktør.
Ny adresse: Buchwaldsgade 15, 1. tv, 5000 Odense C
Stiftelsesdato: 23.07.2021.
Virkningsdato: 23.07.2021.
Seneste vedtægtsdato: 23.07.2021.
Kapital:
kr. 40.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 40.000,00 til kurs 100,00, fuldt indbetalt.
Stifter:
CVR-NR. 42559903 Omixholding ApS, Solbærvej 8, Hjallese, 5260 Odense S, den 23.07.2021.
Direktion:
Morten Østergaard Andersen, den 23.07.2021.
Selskabet tegnes af en direktør eller den samlede direktion.
Første regnskabsår:
23.07.2021 - 31.12.2022.
Regnskabsår:
01.01 - 31.12.
Formål:
Selskabets formål er at udvikle og sælge bioteknologiske produkter.
P-number 1027391032Kochsgade 25, 5000 Odense C
No other current company drawn.